Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials

[1]  Y. Hayashi,et al.  Comparison of Everolimus-Eluting and Sirolimus-Eluting Coronary Stents: 1-Year Outcomes from the Randomized Evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial (RESET) , 2012, Circulation.

[2]  P. Serruys,et al.  Very Late Coronary Stent Thrombosis of a Newer-Generation Everolimus-Eluting Stent Compared With Early-Generation Drug-Eluting Stents: A Prospective Cohort Study , 2012, Circulation.

[3]  M. Jeong,et al.  Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial. , 2011, Journal of the American College of Cardiology.

[4]  I. Seong,et al.  Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: a randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III) Trial. , 2011, JACC. Cardiovascular interventions.

[5]  M. Hadamitzky,et al.  Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. , 2011, Journal of the American College of Cardiology.

[6]  I. Seong,et al.  Randomized Comparison of Everolimus-Eluting Stent Versus Sirolimus-Eluting Stent Implantation for De Novo Coronary Artery Disease in Patients With Diabetes Mellitus (ESSENCE-DIABETES): Results From the ESSENCE-DIABETES Trial , 2011, Circulation.

[7]  A. Kastrati,et al.  Everolimus-Eluting Versus Sirolimus-Eluting StentsClinical Perspective , 2011 .

[8]  A. Kastrati,et al.  Everolimus-Eluting Versus Sirolimus-Eluting Stents: A Meta-Analysis of Randomized Trials , 2011, Circulation. Cardiovascular interventions.

[9]  A. M. Leone,et al.  Prospective randomized comparison of sirolimus- or everolimus-eluting stent to treat bifurcated lesions by provisional approach. , 2011, JACC. Cardiovascular interventions.

[10]  A. Kastrati,et al.  Long-term outcome after sirolimus-eluting stents versus bare metal stents in patients with Diabetes mellitus: a patient-level meta-analysis of randomized trials , 2011, Clinical Research in Cardiology.

[11]  F. Eberli,et al.  Drug-eluting versus bare-metal stents in large coronary arteries. , 2010, The New England journal of medicine.

[12]  M. Pittler.  Systematic Reviews in Health Care: Meta‐analysis in Context , 2010 .

[13]  H. Sørensen,et al.  Rationale and Design of a Randomized Clinical Comparison of Everolimus-Eluting (Xience V/Promus) and Sirolimus-Eluting (Cypher Select+) Coronary Stents in Unselected Patients with Coronary Heart Disease , 2010, Cardiology.

[14]  Gregg W Stone,et al.  Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. , 2010, The New England journal of medicine.

[15]  Tibor Schuster,et al.  Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages , 2010, PLoS medicine.

[16]  A. Kastrati,et al.  Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials , 2010, Clinical Research in Cardiology.

[17]  P. Smits,et al.  Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial , 2010, The Lancet.

[18]  P. Serruys,et al.  Xience V™ everolimus-eluting coronary stent , 2009, Expert review of medical devices.

[19]  P. Fitzgerald,et al.  Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. , 2008, JAMA.

[20]  M. Pfisterer,et al.  A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. , 2007, Journal of the American College of Cardiology.

[21]  Simon Wandel,et al.  Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis , 2007, The Lancet.

[22]  C. Nienaber,et al.  The Sirolimus-eluting coronary stent in daily routine practice in Germany: , 2007, Clinical Research in Cardiology.

[23]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[24]  Marco Valgimigli,et al.  Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.

[25]  S. Pocock,et al.  Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. , 2007, The New England journal of medicine.

[26]  P. Serruys,et al.  A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial. , 2006, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[27]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[28]  D. Altman,et al.  Systematic reviews in health care : meta-analysis in context , 2001 .

[29]  D. Altman,et al.  Concealing treatment allocation in randomised trials , 2001, BMJ : British Medical Journal.

[30]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[31]  W. Rottbauer,et al.  Everolimus-eluting stents for treatment of chronic total coronary occlusions , 2011, Clinical Research in Cardiology.

[32]  Douglas G. Altman,et al.  Systematic Reviews in Health Care , 2001 .